2022 Inspiring Women in STEM Conference

AGENDA

8:30 a.m. – 9:00 a.m. Registration & Networking Breakfast

9:00 a.m. – 9:10 a.m. Welcome & Opening Remarks
9:10 a.m. – 9:55 a.m.
• Debbie Hart, MS, President & CEO, BioNJ
• Video: Congresswoman Bonnie Watson Coleman Special Message
• Raquel Mura, Head of R&D North America Global R&D Operations, Sanofi

Opening Keynote: Finding Your Edge: Turning Adversity into Advantage
Laura Huang, Ph.D., Professor, Harvard Business School & Author

Join us for an inspiring, empowering and interactive talk with Harvard Business Professor
Laura Huang, who draws upon her tenure in investment banking to show how to overcome
perceptions in order to gain an edge toward a more equitable workplace. Learn how women
entrepreneurs and leaders are taught that hard work is the key to success only to experience
something very different in their everyday work lives. Laura will show us how to overcome
preconceived conceptions and stereotypes by being authentic and distinct. You won’t want
to miss this presentation!

9:55 a.m. – 10:25 a.m. Fireside Chat: Inspiring Women Who Found Their Edge
10:25 a.m. – 10:45 a.m. Hear how these incredible women reached leading roles within their organizations…
transforming challenges into opportunities along the way.
Panelists:

• Marisol Mendez Peron, MS, Senior Vice President, Global Communications &

Corporate Affairs, Genmab

• Christine Ann Miller, MBA, President & CEO, Melinta Therapeutics

Interviewer: Mandy Fahey, Executive Director, Corporate Communications, Insmed Incorporated

Networking Break and Exhibitor Showcase

10:45 a.m.– 11:40 a.m. Investing in Women: Driving Innovation – Intrapreneurship & Entrepreneurship –
Moving Your Idea Forward
Learn how to advance your innovation in a variety of settings, how to access resources
in order to forge ahead and what investments and developments are being made in the
industry in New Jersey.

Panelists:

• Mee Eriksson, CEO, NeurotechR3, Inc.
• Maribel Hernandez, Vice President Clinical Operations and Special Clinical,

PTC Therapeutics

• Ginger Liau, MBA, Partner, Bio Fund at Andreessen Horowitz, a16z
• Ninette Van Lingen, MBA, Senior Director, Strategic Key Accounts Pharma Services

Group, Thermo Fisher Scientific

Moderator: Kara Moore, MLS, Sector Lead, Life Sciences, New Jersey Economic
Development Authority (NJEDA)

11:40 a.m. – 12:00 p.m. Quick Update: Dobbs v. Jackson Impact on Hiring and Recruiting, Travel & Lodging
Benefits and Lifestyle Accounts

Recent data will be shared on how this landmark decision impacts where people want
to work as well as how it may be changing hiring and recruiting efforts, including what
companies are doing to ensure access to reproductive benefits, travel and lodging benefits
and lifestyle accounts.

• Julie Campbell, Principal, Mercer Total Health Team

12:00 p.m. – 1:00 p.m. AGENDA

Networking Lunch and Exhibitor Showcase

1:00 p.m. – 1:45 p.m. Workshop: Empowering Ourselves and Others
Within small working groups, we’ll use “real life” scenarios to highlight ways to use our
emotional intelligence to empower ourselves AND others. Walk away with actionable items
that you can incorporate into your daily lives.

Co-Facilitators:

• Lynne Anderson, Partner, Faegre Drinker Biddle & Reath
• Juliet Hart, CEO & Founder, Hart & Chin

Scan QR Code for a Copy of the Workshop Presentation.

1:45 p.m. – 2:15 p.m. Health Equity – Equitable Access to Medicines and Treatments
All individuals and communities should have equitable access to medicines and treatments.
During this session, we’ll discuss initiatives in New Jersey to reduce health disparities
through policy solutions and community centered solutions.

• Barbara George Johnson, MPH, J.D., Vice President, External Affairs and Urban Policy,

John S. Watson Institute for Urban Policy and Research

Interviewer: Judith Sheft, MBA, Executive Director, New Jersey Commission on Science,
Innovation and Technology

2:15 p.m. – 2:45 p.m. Closing Keynote: From the Locker Room to the Board Room
Lisa Kaplowitz, Co-founder and Executive Director, Rutgers Center for Women in Business
& Assistant Professor, Professional Practice-Finance, Rutgers Business School

Lisa Kaplowitz will leave us energized and ready to take next steps to move our careers
forward by sharing lessons, behaviors and skills learned through sports.

2:45 p.m. – 3:00 p.m. Closing Remarks

• Debbie Hart, MS, President & CEO, BioNJ

SPEAKERS

Lynne Anderson, Partner, Faegre Drinker Biddle & Reath
Ms. Anderson counsels employers on the ever-expanding maze of labor and employment laws and
tenaciously represents their interests during litigation. She is an experienced jury and bench trial
lawyer with a track record of success in whistleblower/retaliation cases, discrimination claims and
restrictive covenant disputes. As a leader of the firm’s gender and pay equity team, Ms. Anderson
helps multistate clients comply with emerging equal pay laws. Additionally, she effectively counsels
clients who are dealing with frontline employee issues and restructuring.

Julie Campbell, Principal, Mercer Total Health Team
Ms. Campbell is a Principal in Mercer’s New York office and a member of Mercer’s Total Health
Management team. She focuses on developing comprehensive health and wellness strategies for
employer clients, with an expertise in women’s and reproductive health and inclusive family planning
approaches. Ms. Campbell has worked with a variety of clients to develop, implement and evaluate
both domestic and global health management strategies and programs. Prior to joining Mercer, Ms.
Campbell worked at the National Business Group on Health and co-wrote an employer toolkit on
Stress Management Strategies & Interventions.

Mee Eriksson, CEO, NeuroTechR3, Inc.
Ms. Eriksson is the CEO and co-founder of NeuroTechR3, a Biomedical Device/Digital Health start-
up that develops affordable and versatile neurorehabilitation technologies to help people recover
hand and arm function after a brain injury, such as stroke and cerebral palsy. Ms. Eriksson has a
strong background of over 20 years of international leadership experience in working with strategic
planning and organizational development. Her extensive knowledge of business development,
combined with her proven ability to create long-lasting partnerships, is a great addition to a team of
highly specialized researchers and engineers.

Mandy Fahey, Executive Director, Corporate Communications, Insmed Incorporated
Ms. Fahey is a seasoned communications leader with nearly 20 years of experience in the health
care and biopharma industries. She leads the Corporate Communications team at Insmed, a
global biopharmaceutical company on a mission to transform the lives of patients with serious
and rare diseases, where she is responsible for internal and external communications, product
communications, and corporate social responsibility. She is also a member of Insmed’s ESG Working
Group. Ms. Fahey is passionate about helping companies tell their stories in a clear and powerful
way that resonates with multiple audiences, while putting Patients at the center.

Barbara George Johnson, MPH, J.D., Vice President, External Affairs and Urban
Policy, John S. Watson Institute for Urban Policy and Research
Ms. George Johnson brings more than 30 years of experience as a public policy professional. She
has become a leading voice in shaping economic, health and social policy in New Jersey. Currently,
Ms. George Johnson is the Vice President of External Affairs and Urban Policy at Kean University,
where she oversees the John S. Watson Institute for Urban Policy and Research. She earned a MPH
from Columbia University School of Public Health and a Law degree from Rutgers-Newark Law
School.

SPEAKERS

Debbie Hart, MS, President & CEO, BioNJ
Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in
1994. Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a
respected thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become
the trusted voice of the life sciences industry in New Jersey – working directly with legislative leaders
in both Trenton and Washington D.C. to advance the life sciences industry, foster medical innovation
and patient access while ensuring health equity and healthcare affordability. Most recently, she was
named by Governor Murphy as the Chair of the New Jersey Commission on Science, Innovation and
Technology.
Juliet Chin Hart, Founder & CEO, Hart & Chin Associates, LLC
Ms. Hart is the founder of Hart & Chin, a company that offers workshops, coaching and consulting
services. She believes that strengthening the leadership and interpersonal skills of scientists will
make them more effective leaders, who will have a larger impact and create greater value for the
organizations they serve. Previously working as a scientist at Johnson & Johnson, she has seen the
impact of her work drive employee engagement, increased collaboration and stimulate innovation
across functions. She has led trainings on developing leadership and management skills, cross-
cultural awareness, presentation pitching and communications skills.

Maribel Hernandez, Vice President Clinical Operations and Special Clinical,
PTC Therapeutics
Ms. Hernandez is the Vice President, Clinical Operations and Special Projects overseeing all clinical
trial activities and processes at PTC Therapeutics. Prior to joining PTC, she was the U.S. Head of
Clinical Operations at Eisai, a global pharmaceutical company, in the Neuroscience Business Unit.
Prior to that, Ms. Hernandez was at Synergy Pharmaceuticals and Pfizer, where she held several roles
within central research, clinical data operations and development operations. Ms. Hernandez is also
a licensed and certified physician assistant in internal medicine/pediatrics. She practiced for six years
in the medical office and clinic settings.
Laura Huang, Ph.D., Professor, Harvard Business School and Author
Professor Huang is an associate professor of business administration in the Organizational Behavior
Unit. Prior to joining HBS, she was an assistant professor of management at the Wharton School,
University of Pennsylvania. Professor Huang’s research examines early stage entrepreneurship, and
the role of interpersonal relationships and implicit factors in the investment decisions of financiers
such as angel investors and VCs. Her work studies the subtle signals and cues that often impact the
behavioral perceptions of investors, which can lead to implicit bias in the investing process.

Lisa Kaplowitz, Co-founder and Executive Director, Rutgers Center for Women in
Business
Ms. Kaplowitz is the Co-founder and Executive Director of the Rutgers Center for Women in
Business, and assistant professor of finance at Rutgers Business School, where she leverages 25+
years of experience as an investment banker and CFO. Ms. Kaplowitz’s advocacy began as a scholar-
athlete at Brown University, when she was part of a landmark Title IX case that added more varsity
athletic opportunities for women. Today, she continues to champion gender equity at work and in
the home, alongside her husband and teenage sons, where you can see them in action in her latest
TEDx, Advancing Women in the Workplace, One Son at a Time.

SPEAKERS

Ginger Liau, MBA, Partner, Bio Fund at Andreessen Horowitz, a16z
Ms. Liau is a partner with the bio and health fund at Andreessen Horowitz, where she is focused on
business development for early stage therapeutics and life sciences companies. Prior to joining a16z,
she held a variety of roles at Alnylam Pharmaceuticals, ranging from a chemist in the RNA synthesis
lab to strategy and operations positions across business planning, program management and
investor relations. Ms. Liau has an MBA from Stanford University and a BA in Chemistry and Math
from Vanderbilt University.

Marisol Mendez Peron, MS, Senior Vice President, Communications & Corporate
Affairs, Genmab
Ms. Peron is an accomplished communications leader with 25 years of experience in the life
sciences pharmaceutical and biotech industry. She is responsible for the strategic management and
development of communications programs, issues management, corporate social responsibility,
Patient advocacy and corporate affairs for Genmab, an international biotech working to transform
the future treatment of cancer. With the CEO, Ms. Peron co-chairs the company’s CSR Committee
where a key focus is centered around Genmab’s commitment to sustainability and furthering the
company’s ESG strategy.
Raquel Mura, Head of R&D North America Global R&D Operations, Sanofi
Ms. Mura provides strategic and operational leadership to deliver an industry-leading environment
for R&D teams in North America to maximize the value of the pipeline and bring transformative
drugs with pace to Patients. A passionate advocate for purpose driven and inclusive leadership, she
has led strategy and operations teams across different regions in regulatory and innovation functions
and drove transformation initiatives including integration of business assets, change management
and implementation of best-in-class industry capabilities. She is currently Executive Sponsor of the
Sanofi R&D NA D&I Working Group and a member of the HBA Gender Parity Collaborative.

Christine Ann Miller, MBA, President & CEO, Melinta Therapeutics
Ms. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences.
Prior to joining Melinta, Ms. Miller led the global and U.S. product portfolio for Sandoz, where she
was accountable for transitioning the portfolio toward rapid-growth and higher-margin segments,
such as complex generics and value-added medicines, while continuing to build the branded
generics business. Among her various achievements, Ms. Miller directed more than 50 product
launches that generated over $300 million of new annual revenue, closed numerous business
development acquisitions and built a robust five-year development and acquisition product pipeline.

Kara Moore, MLS, Sector Lead, Life Sciences, New Jersey Economic Development
Authority (NJEDA)
Ms. Moore is the Sector Lead for Life Sciences at the New Jersey Economic Development Authority.
She is focused on working with organizations across the State in this sector on growing and
innovating in the state of New Jersey. Prior to the NJEDA, she led efforts connecting corporate
partners to researchers at Rutgers University and Northwestern University. She holds a Master of
Information Science from Indiana University.

SPEAKERS

Judith Sheft, MBA, Executive Director, New Jersey Commission on Science,
Innovation and Technology (NJCSIT)
Ms. Sheft is the Executive Director of the New Jersey Commission on Science, Innovation and
Technology. The Commission’s mission is to accelerate economic development by stimulating
academic-industrial collaboration and encouraging and supporting entrepreneurs and inventors.
Previously she worked at NJIT managing the HealthIT Connections entrepreneurial cluster
development program, the NJIT I-Corps Site and the Procurement Technical Assistance Center.
Ms. Sheft is on the Board of Advisors to the NJIT Murray Women’s Center and serves as a mentor
and on the Board of Greater Newark Enterprise Corporation, Women’s Center for Entrepreneurship
Corporation, Einstein’s Alley, SheTek and NJEDA Technology Advisory Board.

Ninette Van Lingen, MBA, Senior Director, Strategic Key Accounts Pharma Services
Group, Thermo Fisher Scientific
Ms. Ninette van Lingen has 20 plus years of commercial experience in technology and life
sciences. She began her career in a privately held company, serving both the semiconductor and
pharmaceutical industries in various roles, including sales, marketing and product development.
For the past 15 years she has worked in the pharmaceutical industry in the continuum of drug
development and clinical trials. She’s managed high performing teams and is still passionate about
technology and medicines improving the world we live in.

THANK YOU TO OUR SPONSORS

Sanofi: We are an innovative global health care company, driven by one purpose: we chase
the miracles of science to improve people’s lives. Our team, across some 100 countries, is
dedicated to transforming the practice of medicine by working to turn the impossible into
the possible. We provide potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting sustainability and social responsibility
at the center of our ambitions.
PTC is a science-driven, global biopharmaceutical company focused on the discovery,
development and commercialization of clinically differentiated medicines that provide
benefits to Patients with rare disorders. PTC’s ability to innovate to identify new therapies
and globally commercialize products is the foundation that drives investment in a robust
and diversified pipeline of transformative medicines. Our mission is to provide access to
best-in-class treatments for Patients who have little to no treatment options. PTC leverages
its strong scientific and clinical expertise and global commercial infrastructure to bring
therapies to Patients. We believe this allows us to maximize value for all our stakeholders.
Amicus Therapeutics is a global, Patient-dedicated biotechnology company focused on
discovering, developing and delivering high-quality medicines for people living with rare
metabolic diseases.

Drew University offers its diverse community of learners a challenging education shaped
by a deep-rooted culture of faculty-student mentorship. Drew’s Madison campus provides
distinctive and flexible advanced degree programs to fit professional goals at any stage of
one’s career and to meet the competing needs of busy schedules. Our Caspersen School
of Graduate Studies offers Certificate, Master’s and Doctoral programs in a range of fields
including Medical & Health Humanities, Finance and Data Analytics. Humanizing medicine
and care by fostering moral practices and institutions is the mission of the low-residency
Medical & Health Humanities program. For more, visit drew.edu/bionj
Faegre Drinker’s Health & Life Sciences Industry Team is built from our interdisciplinary
practice groups, comprised of attorneys who have experience, knowledge and insights
about navigating this fast-paced, heavily regulated environment. We can support you
through scientific research, life sciences product development, intellectual property
protection, employment issues and litigation, product marketing and sales, health care
delivery and more. Whether you’re facing issues relating to business and financing
pressures, regulatory scrutiny, workforce management or litigation threats, we stand ready to
provide collaborative and strategic advice.
Genmab is an international biotechnology company with a core purpose guiding its
unstoppable team to strive towards improving the lives of Patients through innovative and
differentiated antibody therapeutics. For more than 20 years, its passionate, innovative
and collaborative team has invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has resulted in a proprietary
pipeline including bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug conjugates. For more
information, please visit Genmab.com.

THANK YOU TO OUR SPONSORS

Innovation+ is a community of engaged entrepreneurs and innovators designed to
strengthen and diversify our workforce and enhance the innovation ecosystem. It empowers
collaborative relationships across industry, education, government and nonprofits to solve
society’s biggest challenges.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the
lives of Patients with serious and rare diseases. Insmed’s first commercial product is a first-
in-disease therapy approved in the United States, Europe and Japan. The company is also
progressing a robust pipeline of investigational therapies targeting areas of serious unmet
need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders.
Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in
Japan. For more information, visit www.insmed.com.
Marsh and Mercer are part of Marsh McLennan, the world’s leading professional services
firm in the areas of risk, strategy and people. We are global businesses united by a
common purpose and a uniquely collaborative culture. Our 76,000 colleagues advise
organizations in over 130 countries, helping them navigate an increasingly dynamic and
complex environment. We are committed to each other, to our clients and to the greater
good. Every day, we help clients change what’s possible, enabling enterprise around the
world, through our businesses.
Melinta Therapeutics provides innovative therapies to people impacted by acute and
life-threatening illnesses. With an unsurpassed commitment to providers and the patients
they serve, the company works to ensure that all people who need its therapies can receive
them. We are seeking to build a legendary company with a passionate team focused on
meeting the unmet needs of our Patients. Over the next years, we want to drive growth
from our current antibiotic portfolio while acquiring synergistic and innovative products in
other therapeutic areas to become a diversified pharma company targeting the hospital
ecosystem.
Merck has a strong history of success in translating cutting-edge research into life-saving
medical breakthroughs. Our scientific advances have made a difference in the lives of
millions of patients worldwide. From Merck’s development of the first measles and mumps
vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth
innovative new medicines. We operate in more than 140 countries and had sales of more
than $48 billion in 2021. We believe that by working together we can play a major role in
transforming global health care. Together we can invent for life. Learn more at
www.merck.com/licensing.
The New Jersey Economic Development Authority (NJEDA) grows the State’s economy
and increases equitable access to opportunity by supporting high-quality job creation,
catalyzing investment, and fostering vibrant, inclusive community development. NJEDA
works in partnership with a diverse range of stakeholders to implement programs and
initiatives that improve quality of life, enhance economic vitality and strengthen New
Jersey’s long-term economic competitiveness.

THANK YOU TO OUR SPONSORS

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the
country’s leading innovative biopharmaceutical research companies, which are devoted to
discovering and developing medicines that enable Patients to live longer and healthier lives.
PhRMA is committed to advancing public policies in the United States and around the world
that support innovative medical research, yield progress for Patients today and provide
hope for the treatments and cures of tomorrow.
Progyny is a leading fertility and family building benefits solution for self and fully
insured organizations, serving populations in the U.S., Canada and globally. Progyny’s
comprehensive and equitable benefit includes access to a large, actively managed network
of top fertility specialists, dedicated concierge Patient support, integrated pharmacy and
wrap-around technology connecting the entire benefit, including an ability to report on
actual outcomes. All together, Progyny generates life-changing outcomes for its 5.4 million
members and savings for 370 employer clients.
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more
than $40 billion and approximately 100,000 employees globally. Our mission is to enable
our customers to make the world healthier, cleaner and safer. We help our customers
accelerate life sciences research, solve complex analytical challenges, improve Patient
diagnostics, deliver medicines to market and increase laboratory productivity. For more
information, please contact Kristin Roosevelt at [email protected], or
610-453-0370.
Tris Pharma Inc. is a leading privately-owned biopharmaceutical company in the U.S.
with a focus on development and commercialization of innovative medicines that address
unmet patient needs. We have more than 150 U.S. and International patents including
applications and have marketed several branded and generic products in the U.S., have
licensed our products in the U.S. and international markets and have a robust pipeline of
innovative products spanning neuroscience and other therapeutic categories employing
our proprietary science and technology. Our science and technology make us unique, but
it is our team members that set us apart; they are the engine that fuels Tris’ passion and
innovation.

Scan this QR Code to take a short survey about
today’s Inspiring Women in STEM Conference.